Loading...

ReproCELL Incorporated

4978.TJPX
Healthcare
Biotechnology
¥215.00
¥3.00(1.42%)

ReproCELL Incorporated (4978.T) Company Profile & Overview

Explore ReproCELL Incorporated’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

ReproCELL Incorporated (4978.T) Company Profile & Overview

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.

SectorHealthcare
IndustryBiotechnology
CEOShuji Yokoyama

Contact Information

81 45 475 3887
MetLife Shin-Yokohama Building, Yokohama, 222-0033

Company Facts

96 Employees
IPO DateJun 26, 2013
CountryJP
Actively Trading

Frequently Asked Questions

;